Major Liver Resection for Hilar Cholangiocarcinoma

Bengmark, S; Ekberg, Henrik; Evander, A.; Klöfver-Ståhl, B.; Tranberg, Karl‐Göran

doi:10.1097/00000658-198802000-00002

Cited by 159 publications

(76 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12,16,19,22,[31][32][33][34][35][36][37] We have established two distinct techniques for reducing the risk of postoperative hepatic insufficiency. One is a safe and reliable method for biliary decompression, 41 and the other is a preoperative portal embolization technique.…”

Section: Discussionmentioning

confidence: 99%

Improved Surgical Results for Hilar Cholangiocarcinoma With Procedures Including Major Hepatic Resection

Kosuge¹,

Yamamoto²,

Shimada³

et al. 1999

Annals of Surgery

319

236

View full text Add to dashboard Cite

ObjectiveTo evaluate the long-term outcome of aggressive surgery incorporating hepatic resection and systematic nodal dissection for advanced carcinoma involving the hepatic hilus. Summary Background DataFew long-term results are available regarding radical surgery incorporating major hepatectomy and nodal dissection. MethodsA retrospective analysis was undertaken in 107 patients with carcinoma involving the hepatic hilus treated between 1980 and 1997. Resectional surgery was performed in 65 patients, 52 of whom underwent major hepatectomies. The effects of clinical and pathologic factors were assessed by univariate and multivariate analyses. ResultsSixty percent of the patients with resectional surgery had stage IVA or IVB disease, and 92.3% of them underwent major hepatectomies. No in-hospital deaths were encountered in the 35 most recent resections, whereas there were six deaths in the early period. Resectional surgery was associated with a survival benefit, especially when resection margins were free from cancerous infiltration. The estimated 5-year survival rate after resection, including all deaths, was 34.8%; this was 51.6% when the margins were clear. Nodal involvement was documented in 44.6% of the resections. However, patients with metastases limited to the regional nodes showed a survival rate similar to that in patients without nodal involvement. Significant predictive factors for survival after resection were extension to the gallbladder, nodal status, resectional margins, histologic type, and gender.

show abstract

Section: Discussionmentioning

confidence: 99%

Improved Surgical Results for Hilar Cholangiocarcinoma With Procedures Including Major Hepatic Resection

Kosuge¹,

Yamamoto²,

Shimada³

et al. 1999

Annals of Surgery

319

236

View full text Add to dashboard Cite

show abstract

“…Excision of the caudate lobe was done in 20 of the 28 (71 %) patients (10,(22)(23)(24). Systematic lymph node dissection was done in 24 (86%) patients (10,12,26,27). There were nine vascular reconstructions, including: four segmental excision of main portal vein; one primary reconstruction of right portal vein; two segmental excisions of right hepatic artery; one primary reconstruction of the artery of the left lateral segment; and one replacement of both the main portal vein and proper hepatic artery graft with cadaver iliac vein and artery grafts, respectively (28)(29)(30)(31)(32)(33).…”

Section: Surgical Proceduresmentioning

confidence: 99%

Liver Resection for Hilar and Peripheral Cholangiocarcinomas: A Study of 62 Cases

Madariaga¹,

Iwatsuki²,

Todo³

et al. 1998

Annals of Surgery

239

144

View full text Add to dashboard Cite

MINI ABSTRACTWe present our 14-year experience of liver resection for hilar and peripheral cholangiocarcinomas with an analysis of the clinical and pathologic prognostic factors, overall survival and disease-free survival. ResultsThe survival rates for HCCA and PCCA at one-year were 79% (± 8%) and 67% (± 8%); at three years, 39<'10 (± 10%) and 40% (± 9%); and at five years, 8% (± 7%) and 35% (± 10%), respectively. The disease-free survival rates for HCCA and PCCA were 85% (±1O%) and 77% (±9<'Io) at 1 year; 18% (±11%) and 41% (± 12%) at 3 years; and 18% (±11 %) and 41 % (±12%) at 5 years, respectively. With HCCA, no risk factors were associated with patient survival. For PCCA, multiple tumors (RR=3.5; 95% confidence interval=1.2 to 10.5) and incomplete resection (RR=8.3; 95% confidence interval=2.3 to 29.6) were independently associated with a worse prognosis. For HCCA, there was a trend for lower disease-free survival in female patients (p=O.056; logrank test). For PCCA, tumor size greater than 5 cm was the only factor associated with disease-recurrence (p=0.024; logrank) . Postoperative morbidity and mortality (30 day) were 32% and 14%, respectively for HCCA, and 24% and 3 6% forPCCA. ConclusionsEven though rare, five year survival by resection can be achieved in both HCCA and PCCA; but new adjuvant treatments are clearly needed. ABSTRACTBackground. Long term survival achieved after surgical treatment of hilar

show abstract

“…However, the operative mortality is high and the 5-year survival rate remains disappointing (7). Local tumor recurrence is the major cause of death for patients who undergo resection (8).…”

Section: Introductionmentioning

confidence: 99%

Berberine Inhibits Growth and Induces G1 Arrest and Apoptosis in Human Cholangiocarcinoma QBC939 Cells

Wang

Zhuang

et al. 2012

J Pharmacol Sci

View full text Add to dashboard Cite

Abstract. The chemotherapeutic approach using non-toxic natural products may be one of the strategies for the management of the cholangiocarcinoma. Here we report that in vitro treatment of human cholangiocarcinoma QBC939 cells with berberine, a naturally occurring isoquinoline alkaloid, decreased cell viability and induced cell death in a dose-dependent manner, which was associated with an increase in G1 arrest. Our western blot analysis showed that berberine-induced G1 cell cycle arrest was mediated through the increased expression of cyclin-dependent kinase inhibitors (Cdki) proteins (Cip1/p21 and Kip1/p27); a simultaneous decrease in Cdk2 and Cdk4 and cyclins D1, and reduced activity of the Cyclins-Cdk complex. In additional studies, treatment of QBC939 cells with different concentrations (10, 40, 80 μM) of berberine for 48 h resulted in a significant dose-dependent increase in apoptosis compared to the non-berberine-treated control, which was associated with an increased expression of pro-apoptotic protein Bax and decreased expression of anti-apoptotic proteins Bcl-2 and Bcl-xL. Together, this study for the first time identified berberine as a chemotherapeutic agent against human cholangiocarcinoma cells QBC939 cells in vitro. Further in vivo studies are required to determine whether berberine could be an effective chemotherapeutic agent for the management of cholangiocarcinoma.

show abstract

Major Liver Resection for Hilar Cholangiocarcinoma

Cited by 159 publications

References 13 publications

Improved Surgical Results for Hilar Cholangiocarcinoma With Procedures Including Major Hepatic Resection

Improved Surgical Results for Hilar Cholangiocarcinoma With Procedures Including Major Hepatic Resection

Liver Resection for Hilar and Peripheral Cholangiocarcinomas: A Study of 62 Cases

Berberine Inhibits Growth and Induces G1 Arrest and Apoptosis in Human Cholangiocarcinoma QBC939 Cells

Contact Info

Product

Resources

About